In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical (NASDAQ:OHRP) with a $34 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 …
